Surgery for extrahepatic cholangiocarcinoma includes radical resection and palliative resection. A part of advanced cholangiocarcinoma can be effectively relieved from jaundice through PTC or ERCP by placing an endoprosthetic tube. 1.Surgical methods for cholangiocarcinoma of the hilar region (1)，Radical resection of cholangiocarcinoma of the hilar region includes skeletal excision of part of the common bile duct, gallbladder, common hepatic duct, left and right hepatic ducts and hepatoduodenal ligament, except for blood vessels, and Roux-Y anastomosis of hepatic duct and jejunum. (2) Expanded resection of hepatoportal cholangiocarcinoma is performed at the same time as skeletal resection, with simultaneous resection of the left hemisphere, right hemisphere, middle hepatic lobe or caudate lobe. When the portal vein wall is involved, it can be partially resected or reconstructed after whole segment resection. (3) Partial resection of hilar cholangiocarcinoma, memory alloy endoprosthesis in the stenosed hepatic duct and Roux-Y anastomosis of the hepatic duct and jejunum. The stent can dilate the narrowed bile duct and delay the bile duct obstruction due to tumor residual or recurrence. (4) Palliative reduction of yellow drainage includes internal or external drainage of hepatic ducts, left intrahepatic bile duct jejunostomy, right intrahepatic bile duct jejunostomy, external drainage of u-shaped ducts, and memory alloy internal stenting. For those who are not suitable for surgery, PTCD or ERCP internal stent implantation and drainage can also be performed. 2.Surgical methods for middle bile duct cancer: partial resection of bile duct, Roux-Y anastomosis of hepatic duct and jejunum, partial resection or partial resection of portal vein wall. For those who cannot be resected, internal or external biliary bypass drainage is performed above the obstruction. 3.The standard surgical method for lower bile duct cancer is pancreaticoduodenectomy The 5-year survival rate after resection of hepatoportal cholangiocarcinoma is 40% for the most optimistic, and 10% or less for the others. Local recurrence is the leading cause of death. The survival rate of patients with resected lower cholangiocarcinoma is higher than that of patients with resected hilar cholangiocarcinoma, with one group of studies reporting a 5-year survival rate of up to 28%. The 5-year survival rate of small intrahepatic cholangiocarcinoma can be 44% after hepatic resection, while the prognosis is very poor for huge intrahepatic cholangiocarcinoma which is difficult to be resected. Patients without lymph node metastasis and invasion of large blood vessels inside and outside the liver are eligible for liver transplantation, and in a few studies, the 5-year survival rate after liver transplantation exceeds 53%.